An update on the pharmacological treatment of obsessive-compulsive disorder

  title={An update on the pharmacological treatment of obsessive-compulsive disorder},
  author={L. Fontenelle and A. Nascimento and M. Mendlowicz and R. G. Shavitt and M. Versiani},
  journal={Expert Opinion on Pharmacotherapy},
  pages={563 - 583}
  • L. Fontenelle, A. Nascimento, +2 authors M. Versiani
  • Published 2007
  • Medicine
  • Expert Opinion on Pharmacotherapy
  • The purpose of this article is to introduce the reader to an updated evidence-based drug treatment algorithm to be employed in patients with obsessive-compulsive disorder (OCD). Relevant studies were identified through a comprehensive review and classified according to the type of patients enrolled, the quality of the study design and the invasiveness, availability and complexity of the therapeutic approach. When ineffective, therapeutic trials with first-line strategies (such as the selective… CONTINUE READING
    38 Citations
    Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report
    • Ö. Uzun
    • Psychology, Medicine
    • Journal of psychopharmacology
    • 2010
    • 38
    [Resistance and refractoriness in obsessive-compulsive disorder].
    • 21
    • PDF
    Management of obsessive-compulsive disorder with fluvoxamine extended release
    • 11
    • PDF


    A review of pharmacologic treatments for obsessive-compulsive disorder.
    • 72
    Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder
    • 19
    [Treatment of obsessive-compulsive disorder].
    • 111
    • Highly Influential
    Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    • 253
    • Highly Influential
    • PDF
    Brain stimulation techniques in the treatment of obsessive-compulsive disorder: current and future directions.
    • 43
    • Highly Influential
    • PDF
    Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial
    • 255
    Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
    • 80